Mezzion Pharma is a Seoul, South Korea-based pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics in rare pediatric diseases. The company is working to bring JURVIGO (udenafil), a phosphodiesterase type 5 inhibitor, to market for an estimated global 70,000 single ventricle congenital heart disease (SV-CHD) patients aged 12 and above who have undergone Fontan palliation. Mezzion intends to fund its confirmatory FUEL-2 phase 3 clinical trial and future commercialization efforts with recent financing. It plans regulatory submissions in additional jurisdictions, including Europe. Mezzion is publicly listed on the Korean stock exchange (140410:KOSDAQ) and is led by founder and CEO Dong-Hyun Park. The company and its subsidiary maintain administrative offices in Deerfield, Illinois and Boca Raton, Florida.

Total raised

$40M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2023